



# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit
<b>First Implementation Date:</b>	July 11, 2019
<b>Revised Date:</b>	April 6, 2023
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state specific preferred drug list.

**Why Issue Selected:** Migraine headache is a chronic, debilitating condition that tends to afflict young, productive, and otherwise healthy people. Patients with frequent or severe migraine headaches who are refractory to acute treatments should receive preventative therapy. Calcitonin gene-related peptide (CGRP) mediates trigeminovascular pain from intracranial vessels to the central nervous system. Stimulation of the trigeminal ganglion induces the release of CGRP, and CGRP infusion can trigger a migraine attack. CGRP inhibitors bind to the CGRP receptor and antagonize CGRP receptor function.

Total program savings for the PDL classes will be regularly reviewed.

<b>Program-Specific Information:</b>	<b>Preferred Agents</b>	<b>Non-Preferred Agents</b>
	<ul style="list-style-type: none"><li>• Ajovy®</li><li>• Emgality® 120 mg/mL</li></ul>	<ul style="list-style-type: none"><li>• Aimovig®</li><li>• Emgality® 100 mg/mL</li><li>• <b>Qulipta™</b></li><li>• Vyepti®</li></ul>

**Type of Criteria:** ☐ Increased risk of ADE  
☒ Appropriate Indications

☒ Preferred Drug List  
☐ Clinical Edit

**Data Sources:** ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Age range: All appropriate MO Healthnet

## Approval Criteria

- For Aimovig, Ajovy, Emgality 120 mg/mL, **Qulipta**, or Vypeti
  - For first fill only:

*SmartPA PDL Proposal Form*

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries. Other company trademarks are also acknowledged.

- Documented diagnosis of chronic or episodic migraine **AND**
- History of  $\geq 4$  migraines per month **AND**
- Adequate therapeutic trial of 2 prophylactic options from 2 different categories including:
  - Anticonvulsants: divalproex, valproate, topiramate
  - Antidepressants: amitriptyline, venlafaxine
  - Beta blockers: atenolol, metoprolol, nadolol, propranolol, timolol **AND**
- For non-preferred agents: Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
  - Documented trial period of preferred agents **OR**
  - Documented ADE/ADR to preferred agents
- For Emgality 100 mg/mL
  - Documented diagnosis of episodic cluster headache **AND**
  - Therapeutic trial of verapamil AND topiramate (60/90 days for each) required on first fill only

## Denial Criteria

- For diagnosis of chronic or episodic migraine on the first fill only: Botox therapy in the past 90 days
- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosing limitations on the following:

Drug Description	Generic Equivalent	Max Dosing Limitations
AIMOVIG 140 MG/ML AUTOINJECTOR	ERENUMAB	1 autoinjector per 20 days
AIMOVIG 70 MG/ML AUTOINJECTOR	ERENUMAB	1 autoinjector per 20 days
AJOVY 225 MG/1.5 ML AUTOINJECTOR	FREMANEZUMAB	3 autoinjectors per 76 days
AJOVY 225 MG/1.5 ML SYRINGE	FREMANEZUMAB	3 syringes per 76 days
EMGALITY 100 MG/ML SYRINGE	GALCANEZUMAB	3 syringes per 20 days
<b>QULIPTA 10 MG TABLET</b>	<b>ATOGEPAANT</b>	<b>1 tablet per day</b>
<b>QULIPTA 30 MG TABLET</b>	<b>ATOGEPAANT</b>	<b>1 tablet per day</b>
<b>QULIPTA 60 MG TABLET</b>	<b>ATOGEPAANT</b>	<b>1 tablet per day</b>
VYEPTI 100 MG/ML VIAL	EPTINEZUMAB-JJMR	3 vials per 76 days

## Required Documentation

Laboratory Results: ☐  
MedWatch Form: ☐

Progress Notes: ☒  
Other: ☐

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

6 months

## References

*SmartPA PDL Proposal Form*  
© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.  
Other company trademarks are also acknowledged.

- Evidence-Based Medicine and Fiscal Analysis: “Therapeutic Class Review: CENTRAL NERVOUS SYSTEM: Calcitonin Gene-Related Peptide Receptor Targeted Therapies”, Gainwell Technologies; Last updated October 12, 2022.
- Evidence-Based Medicine Analysis: “Calcitonin Gene-Related Peptide (CGRP) Inhibitors”, UMKC-DIC; August 2022.
- USPDI, Micromedex; 2022.
- Drug Facts and Comparisons On-line; 2022.